Acadia Healthcare, a nationwide chain of psychiatric hospitals, faces new federal charges after it just agreed to a nearly ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

The new drug, Bristol Myers Squibb’s Cobenfy, targets a different area of the brain than traditional antipsychotic drugs to relieve symptoms like delusions without causing patients to gain ...

High MMP9 was associated with poor antipsychotic treatment response and changes in white matter density among patients with schizophrenia.

The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.

The deaths of a couple who were killed by their son could have been avoided if he had been prescribed antipsychotic ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...